CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01883297
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:14.139208+00:00
- Published At
- 2024-09-05T00:00:00+00:00
- Record Updated At
- 2024-09-05
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Recurrent", "Platinum-resistant", "High Grade Serous Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-09-05"- protocolSection.identificationModule.nctId
"NCT01883297"- protocolSection.identificationModule.officialTitle
"Phase I Study Evaluating the Feasibility and Safety of Infusion of \"Re-Stimulated\" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.